Global Hepatitis C Diagnosis and Treatment Market - Overview
Hepatitis C is the inflammation of liver caused by infection by hepatitis C virus characterized by a host of symptoms such as yellowed eyes and skin due to bilirubin, flu-like symptoms which include nausea, vomiting, poor appetite, joint pain, headaches, clay coloured stools etc. According to the World Health Organisation, hepatitis C affects between 130–150 million people globally every year claiming a toll of 700000 lives. Of those who recover about 15-20% develop liver cirrhosis or liver cancer. Free sample copy is available here @ https://www.marketresearchfuture.com/sample_request/1569 Market Players Hoffmann-La Roche Ltd (Switzerland), BMS (U.S), Merck & Co., Inc (U.S), Vertex Pharmaceuticals Incorporated (U.S), Gilead sciences Inc (U.S.)., Abbvie Inc (U.S.), Johnson & Johnson (U.S.), Glaxosmithkline plc (U.K), Novartis AG (Switzerland), Bristol-Myers Squibb (U.S.) are some of the prominent players at the forefront of competition in the Global Hepatitis C Diagnosis and Treatment Market and are profiled in MRFR Analysis. According to Centres for Disease Control & Prevention, in U.S., liver cancer incidence is increasing at a rapid rate (2.3 % per year overall from 2003 – 2012), second only to thyroid cancer. Moreover, the rate of deaths due to liver cancer is increasing faster than for any other type of cancer. Furthermore, Hepatitis B and C are major contributing factors to liver cancer. According to American Cancer Society, Worldwide, the most common risk factor for liver cancer is chronic infection with hepatitis B virus (HBV) or hepatitis C virus (HCV). These infections lead to cirrhosis of the liver and are responsible for making liver cancer the most common cancer globally. The market for hepatitis C diagnosis & treatment is driven by factors such as increasing prevalence of liver cancer, rise in government subsidy and reimbursement especially in U.S., greater screening especially in developing nations, drug abuse and unsafe sex etc. On the other hand, the market constraining factors are self-imitating nature of the disease in a sizable number of patients, challenge of herbal treatment offered at negligible prices especially in developing regions, price war between companies such as between Gilead and Merck, rising urbanization and better sanitation etc. Global Hepatitis C Diagnosis and Treatment Market-Competitive Analysis October, 2013 - Janssen (Parent organisation Johnson & Johnson Services, Inc.) acquired investigational NS5A Inhibitor for the treatment of Hepatitis C from GlaxoSmithKline. According to company reports, GSK2336805 is an investigational NS5a replication complex inhibitor in Phase 2 development for the treatment of chronic hepatitis C in adult patients with compensated liver disease, including all stages of liver fibrosis. October, 2013 - Bristol-Myers Squibb to presented range of new Hepatitis C data at the 2013 American Association for the Study of Liver Diseases (AASLD). According to company reports, Bristol-Myers Squibb’s hepatitis C includes compounds with different mechanisms of action, biologics as well as small molecule direct-acting antivirals. These compounds were being studied as part of multiple treatment regimens with the goal of increasing SVR rates across different patient types. Moreover, company stated NS5A replication complex inhibitor daclatasvir (DCV) had been extensively studied in thousands of patients to date as a foundational agent for multiple DAA-based combination therapies and is currently in Phase III development. DCV has shown antiviral potency and pan-genotypic activity across HCV genotypes in vitro. DCV has a drug-drug interaction profile that supports its continued study in a variety of HCV combination regimens. However, Asunaprevir (ASV) is an NS3 protease inhibitor in Phase III development for hepatitis C as a component of DCV-based treatment regimens. BMS-791325 is a non-nucleoside inhibitor of the NS5B polymerase, currently in Phase II development for hepatitis C as a component of DCV-based treatment regimens. Lambda is an investigational type III interferon that has the potential to offer an alternative to alfa-interferon in patients for whom an interferon-based regimen is required or preferred. Global Hepatitis C Diagnosis and Treatment Market- Regional Analysis Depending on geographic region, Hepatitis C diagnosis & treatment market is segmented into four key regions: Americas, Europe, Asia Pacific, and Middle East & Africa. Globally, Americas is the largest market for global Hepatitis C diagnosis and treatment with Europe in the second position. However, the developed regions market is stagnant and will continue to do so with Asia Pacific region particularly India and China rising fast. Asia pacific region is expected to be fastest growing region in hepatitis C diagnosis & treatment market. The African region is expected to be a laggard and will show at most a moderate rate of growth. Browse Full Report @ https://www.marketresearchfuture.com/reports/hepatitis-c-diagnosis-treatment-market-1569 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients Contact Market Research Future India +1 646 845 9312 Email: [email protected]
0 Comments
Market Scenario
Blood glucose test strip are small & disposable and they are used to monitor the blood glucose level. It plays an important role in the blood glucose monitoring and treatment of diabetes. Total diabetic population in China is 113 million, which accounts 11% of total Chinese population, whereas 67 million people in India have diabetes. Additionally, 20% of population from most of the South Indian cities have diabetes. According to a study, China has the highest smoking rate and smoking increases the chances of developing diabetes by 45% as compare to non-smoker, which, in turn, will drive the growth of the market over the assessment period. Free sample copy is available here @ https://www.marketresearchfuture.com/sample_request/625 Market Players F. Hoffmann-La Roche Ltd (Switzerland), Abbott (US), LifeScan, Inc. (US), i-SENS. Inc. (South Korea), AgaMatrix (US), TaiDoc Technology Corporation (Taiwan), BioSensors, Inc. (US), Universal Biosensors (Australia), Beijing Yicheng Electronic Co., Ltd (China), Hmd Biomedical (Taiwan), and B. Braun Melsungen Ag (Germany). Many countries in Asia Pacific are developing rapidly. The people living in this region are attracted to the western culture and sedentary life, which make them more prone to different metabolic diseases and lifestyle related diseases, for instance, diabetes and obesity. Majority of the population in Asia Pacific region smoke, which is another factor responsible for development of diabetes. Different types of test are available to monitor the blood glucose level such as oral glucose tolerance test, postprandial blood sugar, random blood sugar testing, and others. The blood glucose test strip market is increasing due to increasing diabetic population, developing technology, increasing R &D in diabetes, increasing awareness among the people, and improving diagnosis and treatment techniques for diabetes. On the other hand, high cost of the strips and introduction of sensor technology, which continuously monitor and indicate blood glucose level may hamper the growth of the market. Segmentation Asia Pacific blood glucose test strip market is segmented on basis of types, technology and end users. On the basis of types, the market is segmented into glucose oxidase, glucose dehydrogenase, and other. On the basis of technology, the market is segmented into wicking technology and channel technology. On the basis of end user, the market is categorised in hospital, clinic, homecare, and others Regional Analysis Asia Pacific region is segmented into Japan, China, India, Australia, Republic of Korea, and Rest of Asia Pacific. India and China are two most populated countries in this region, which together accounts for 180 million of diabetic patient. Increasing diabetic population in these countries has attracted many of the multinational companies to enter in the market. Overweight and obesity are majorly responsible for developing diabetes. Additionally, poor diet plan and lack of exercise contribute to the increasing diabetic population and India and China have the huge obese and overweight population. Thus, increasing prevalence of diabetes, & obesity, increasing demand for the homecare devices, and increasing healthcare expenditure drive the market growth. Moreover, increasing per capita income and increasing awareness will push the market growth over the forecasted period. Access Complete Report @ https://www.marketresearchfuture.com/reports/asia-pacific-blood-glucose-test-strip-market-625 About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members. Contact: Market Research Future +1 646 845 9312 Email: [email protected] Although a rare kind of disease, over the past couple of years, the prevalence of Cowden syndrome seems to be increasing. Besides, it being a risk factor for cancerous tumors, the Cowden syndrome is taken seriously, and huge investments are transpired in the development of treatment. With the interventions of advanced technologies, today, specialists are developing breakthrough therapies & treatments that are phenomenally close. Therefore, the market for Cowden syndrome is growing globally. Get free sample @ https://www.marketresearchfuture.com/sample_request/5096 Acknowledging the traction, the market is vibrating with currently, Market Research Future (MRFR) in its recently published study report asserts that the global Cowden syndrome market gaining further prominence will demonstrate a spectacular growth by 2023, surpassing its previous growth records in terms of value with a striking 6.7% CAGR during 2017 – 2023. Global Cowden Syndrome Market – Segments The MRFR analysis is segmented into four key dynamics; By Sites : Breast, Thyroid, Endometrium (uterus), Colorectal, Kidney, and Skin (melanoma), among others. By Treatments : Genetic Testing, Chemotherapy (Anthracyclines, Taxanes, Antimetabolites, Alkylating Agents and others.), Targeted Therapy (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and others.), Surgery & Radiation Therapy, Hormone Therapy (Selective Estrogen-Receptor Modulators (SERMs), Aromatase Inhibitors, and others.). By End-Users : Hospital & Clinics, ambulatory care centers, and others. By Regions : North America, Europe, APAC and the Rest-of-the-World. Global Cowden Syndrome Market – Regional Analysis Additional factors acting as a tailwind to the market growth include high healthcare expenditure, huge technological development, and strong government support for research & development. Simultaneously, the presence of the leading players and increasing availability of funds are impacting the market growth in this region, positively. The European region accounts for the second-largest market for Cowden syndrome treatment, emerging as another lucrative market, globally. Germany, backed by its sizeable medical device industry and its vast Cowden syndrome treatment market is expected to drive the market growth in the region. Favorable governmental support and initiatives drive the growth in the market extensively. The proliferating healthcare sector in the region, backed by the resurging economy is fostering the market growth radiantly. Access Report @ https://www.marketresearchfuture.com/reports/cowden-syndrome-market-5096 Global Cowden Syndrome Market – Competitive Analysis Cowden syndrome market is highly competitive. The key strategies traced from the analysis of recent developments of the key players include product launch, agreement & partnership, acquisition, and expansion. Key manufacturers utilizing breakthrough manufacturing technology strive to develop a comprehensive range of safe and reliable solutions portfolio. Key Players: The global cowden syndrome market is driven by some of the leading players including GlaxoSmithKline Plc. (UK), Novartis AG (Switzerland), Bayer AG (Germany), Eli Lilly and Company (US), Amgen, Inc. (US), AstraZeneca Plc. (UK), Sanofi (France), Bristol-Myers Squibb Company (US), AbbVie Inc. (US), Takeda Pharmaceuticals (Japan), Spectrum Pharmaceuticals Inc. (US), Pfizer, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Merck & Co., Inc. (US), Janssen Biotech, Inc. (US), Oncomed Pharmaceuticals (US), and Immunomedics (US). Industry/Innovation/ Related News: September 21, 2018 - GlaxoSmithKline Plc. (UK), a leading global research-based pharmaceutical and healthcare company partnering with the Tres Cantos Open Lab Foundation (TCOLF), a company addressing the translational and funding gap existing in Global Health (GH) announce additional £5m funding for open innovation research in diseases including rear diseases such as Cowden syndrome impacting the developing world. About Market Research Future: At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services. Contact: Market Research Future +1 646 845 9312 Email: [email protected] Ectropion Market 2019 Global KEY Players, Segmental Overview, Regional Growth and Forecast till 202310/1/2019 Market Highlights Ectropion is an ophthalmologic disorder which causes abnormal outward turning of the eyelid. It usually involves the lower eyelid. It is a common eye disorder among the older population and in people who have undergone eye surgeries or any eye infection. Additionally, factors such as trauma, birth defects, Bell’s palsy, and floppy eyelid syndrome are likely to drive the growth of the ectropion market. Global ectropion market is expected to grow at a CAGR of 6.5% during the forecast period. Regional Analysis The Americas dominates the global ectropion market owing to rising ophthalmological disorders, such as dry eye and uveitis among others and increasing aging population. Additionally, competitiveness among the major players in the North American region are likely to enhance the growth ectropion in the North American region. Similarly, growing government initiatives and funding along with the demand for newer technologies are propelling the growth of the ectropion market in the North American region. For instance, eye care programs such as Eye Care America and VISION USA aims to provide free eye examinations to eligible and uninsured people in the North American region. Get a free sample copy @ https://www.marketresearchfuture.com/sample_request/5818 Europe accounts for the second largest market due to increasing aging mass and rising rates in eye disorders. Additionally, improving government initiatives and increasing healthcare frame along with the rising demand for technologically innovative treatment are driving the growth of the ectropion market in Europe. For instance, Eurostat estimated that over 19.2% of the population in Europe was aged 65 and above. Additionally, according to the United Kingdom Statistics Authority, around 121,736 eye examinations were performed under the Eye Health Examinations Wales (EHEW) scheme. This rising older population and increasing government initiatives are likely to drive the growth of the Ectropion market. Asia Pacific is the fastest growing market for ectropion as it is developing at a very rapid pace and has shown the emergence of many players. Additionally, the increasing prevalence of ophthalmological disorders, increasing healthcare expenditure, and the demand for new treatment options along with multinational companies moving towards the developing nations and setting operational set-ups are likely to drive the growth of the market. India and China are the major contributors to the market growth due to the rapid development of healthcare infrastructure in these regions and increasing demand for improved healthcare services. On the other hand, the Middle East and Africa is expected to witness a limited growth due to limited access and lack of awareness among the population. In the Middle East, the growth of the market is driven by the increasing availability of the advanced healthcare scenario. Segmentation The global ectropion market is segmented on the basis of type, treatment, diagnosis, and end-user. On the basis of type, the market is segmented into involutional ectropion, paralytic ectropion, cicatricial ectropion, mechanical ectropion, and congenital ectropion. On the basis of treatment, the market is segmented into eye drops, artificial tears, horizontal taping of the eyelid, and surgery. On the basis of diagnosis, the market is segmented into physical examination, eye examination, and others. On the basis of end-user, the market is segmented into specialty centers, hospitals, and others. Access Report Details @ https://www.marketresearchfuture.com/reports/ectropion-market-5818 Key Players Some of the key players in the ectropion market are Scope Ophthalmics Ltd, InSite Vision Incorporated, NovaBay Pharmaceuticals, Inc., Thea Pharmaceuticals Limited, Perrigo Laboratories, Merck & Co., Gelderma S.A., and Novartis AG. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
October 2021
Categories |